Provectus Biopharmaceuticals (STU:PXY) Cyclically Adjusted Book per Share: €-0.03 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:PXY Provectus Biopharmaceuticals Inc STU:PXY
35 GF Score
Price €0.05
! 3 Warning Signs
View Full Analysis

What is Provectus Biopharmaceuticals Cyclically Adjusted Book per Share?

Provectus Biopharmaceuticals STU:PXY 35 Cyclically Adjusted Book per Share is €-0.03 as of Mar. 2026. GuruFocus rates STU:PXY with a GF Score™ of 35/100. The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Provectus Biopharmaceuticals's adjusted book value per share for the three months ended in Mar. 2026 was €-0.014. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €-0.03 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Provectus Biopharmaceuticals was -22.90% per year. The lowest was -90.20% per year. And the median was -30.70% per year.

As of today (2026-08-03), Provectus Biopharmaceuticals's current stock price is €0.045. Provectus Biopharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was €-0.03. Provectus Biopharmaceuticals's Cyclically Adjusted PB Ratio of today is .


Provectus Biopharmaceuticals  (STU:PXY) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Provectus Biopharmaceuticals Cyclically Adjusted Book per Share Related Terms


Provectus Biopharmaceuticals Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Provectus Biopharmaceuticals's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Provectus Biopharmaceuticals Cyclically Adjusted Book per Share Chart

Provectus Biopharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.01 0.01 0.00 0.00 -0.02

Provectus Biopharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -0.01 -0.01 -0.02 -0.03

STU:PXY vs PSTV, ALGS, ATNM: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Provectus Biopharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Provectus Biopharmaceuticals Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Provectus Biopharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Provectus Biopharmaceuticals's Cyclically Adjusted PB Ratio falls into.


STU:PXY
35GF Score
Provectus Biopharmaceuticals Inc STU:PXY
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Provectus Biopharmaceuticals Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Provectus Biopharmaceuticals's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.014/330.2130*330.2130
=-0.014

Current CPI (Mar. 2026) = 330.2130.

Provectus Biopharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201606 0.038 241.018 0.052
201609 0.019 241.428 0.026
201612 0.009 241.432 0.012
201703 -0.002 243.801 -0.003
201706 -0.010 244.955 -0.013
201709 -0.017 246.819 -0.023
201712 -0.023 246.524 -0.031
201803 -0.027 249.554 -0.036
201806 -0.031 251.989 -0.041
201809 -0.034 252.439 -0.044
201812 -0.040 251.233 -0.053
201903 -0.043 254.202 -0.056
201906 -0.048 256.143 -0.062
201909 -0.053 256.759 -0.068
201912 -0.056 256.974 -0.072
202003 -0.060 258.115 -0.077
202006 -0.062 257.797 -0.079
202009 -0.061 260.280 -0.077
202012 -0.062 260.474 -0.079
202103 -0.066 264.877 -0.082
202106 -0.005 271.696 -0.006
202109 -0.006 274.310 -0.007
202112 -0.009 278.802 -0.011
202203 -0.011 287.504 -0.013
202206 -0.014 296.311 -0.016
202209 -0.017 296.808 -0.019
202212 -0.014 296.797 -0.016
202303 -0.016 301.836 -0.018
202306 -0.016 305.109 -0.017
202309 -0.017 307.789 -0.018
202312 -0.017 306.746 -0.018
202403 -0.016 312.332 -0.017
202406 -0.017 314.175 -0.018
202409 -0.012 315.301 -0.013
202412 -0.014 315.605 -0.015
202503 -0.011 319.799 -0.011
202506 -0.012 322.561 -0.012
202509 -0.013 324.800 -0.013
202512 -0.013 324.054 -0.013
202603 -0.014 330.213 -0.014

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of €-0.03 mean?
Provectus Biopharmaceuticals (STU:PXY) has a Cyclically Adjusted Book per Share of €-0.03 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Provectus Biopharmaceuticals and its competitors.
Is Provectus Biopharmaceuticals' Cyclically Adjusted Book per Share too high?
Provectus Biopharmaceuticals' current Cyclically Adjusted Book per Share is €-0.03. Overall, Provectus Biopharmaceuticals has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Provectus Biopharmaceuticals' Cyclically Adjusted Book per Share compare to PSTV and ALGS?
Provectus Biopharmaceuticals' Cyclically Adjusted Book per Share of €-0.03 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Provectus Biopharmaceuticals and its competitors. Provectus Biopharmaceuticals's current Cyclically Adjusted Book per Share is €-0.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Provectus Biopharmaceuticals stock overvalued right now?
Provectus Biopharmaceuticals (STU:PXY) has a current Cyclically Adjusted Book per Share of €-0.03. The current Cyclically Adjusted Book per Share is €-0.03. Provectus Biopharmaceuticals' overall GF Score™ is 35/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Provectus Biopharmaceuticals (STU:PXY), the current Cyclically Adjusted Book per Share is €-0.03 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Provectus Biopharmaceuticals Business Description

Other Exchanges PVCT:USA
Address 800 South Gay Street, Suite 1610, Knoxville, TN, USA, 37929
Provectus Biopharmaceuticals Inc is a clinical-stage biotechnology company developing immunotherapy medicines for different diseases based on a class of bioactive synthetic small molecule halogenated xanthenes (HXs). Its flagship HX molecule is named rose bengal sodium (RBS). The company's proprietary, patented, pharmaceutical-grade RBS is the active pharmaceutical ingredient (API) in all its clinical development and non-clinical research programs. It has one operating and reporting segment, namely, the development of immunotherapy medicines.
35GF Score

Get the complete analysis for STU:PXY

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.05
Price